This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of atorfastatin on the cognitive function of patients with vascular cognitive impairment and different apolipoprotein E genotypes

Authors

Gu, Ping, Wang, Jian, Shao, Jia-qing, Du, Hong, Zhang, Kai, Jiang, Wei-min

Journal

Nan Fang Yi Ke Da Xue Xue Bao = Journal Of Southern Medical University, Volume: 30, No.: 3, Pages.: 512-514

Year of Publication

2010

Abstract

Objective: To study the effect of atorfastatin on the cognitive function of patients with vascular cognitive impairment (VCI) and different apolipoprotein E genotypes.; Methods: The ApoE polymorphism was genotyped by PCR sequencing and the patients were divided into Eepsilon4 carrier (epsilon4+) group (n=24) and epsilon4- group (n=51). All the patients were given 20 mg oral atorfastatin every evening. The indices of TC, TG, HDL-C, LDL-C, as well as the scores of MMSE and clock-drawing test were compared between the two groups before and 24 weeks after the treatment.; Results: Compared with those without epsilon4 allele, epsilon4+ patients had obviously increased plasma LDL level and lowered scores of MMSE. Plasma TC, TG and LDL-C were decreased significantly in the two groups after the treatment, and the improvement of TC was greater in patients without epsilon4 allele. The scores of MMSE increased significantly in patients with epsilon4 allele. The improvement in the scores of MMSE and clock-drawing test was greater in epsilon4+ group than in epsilon4- group.; Conclusion: Atorfastatin may improve the cognitive function in patients with VCI carrying epsilon4 allele, the effect of which may not be related to lowed blood lipids.;

Keywords

aged, apolipoproteins e, atorfastatin, cognition disorders, dementia vascular, drug therapy, female, genetics, genotype, heptanoic acids, humans, male, middle aged, neuroprotective agents, pyrroles, therapeutic use

Countries of Study

China

Types of Dementia

Vascular Dementia

Types of Study

Case Control Study

Type of Outcomes

Cognition

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Other